Yet another victim for BLUE H:
>>SEATTLE, Feb. 1 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. announced today an initial public offering of 10,000,000 shares of its common stock at $12.00 per share. All of the shares offered are being sold by ZymoGenetics. The joint book-running managers for the offering are Lehman Brothers Inc. and Merrill Lynch & Co. Bear, Stearns & Co. Inc. and Pacific Growth Equities, Inc. are the co-managers. ZymoGenetics has granted the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of its common stock to cover over-allotments, if any. ZymoGenetics' shares will be quoted on the Nasdaq National Market under the trading symbol ``ZGEN.''
ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic protein-based products for the prevention or treatment of human diseases.
Copies of the final prospectus relating to the offering may be obtained from Lehman Brothers Inc., c/o ADP Financial Services, Prospectus Fulfillment, 55 Mercedes Way, Edgewood, NY 11717, (631) 254-7105; Merrill Lynch & Co, 4 World Financial Center, 5th Floor, New York, NY 10080; Bear, Stearns & Co. Inc., 383 Madison Avenue, New York, NY 10179, (631) 254-7129; or Pacific Growth Equities, Inc., Four Maritime Plaza, San Francisco, CA 94111, (415) 274-6800.
Contact:
Charles E. Hart, Ph.D.
Senior Director of Corporate Communication and Investor Relations
ZymoGenetics, Inc.
(206) 442-6744
www.zymogenetics.com<<
Here's the link to the S-1
sec.gov
Cheers, Tuck |
